

NEWS RELEASE

SHELDON INWENTASH ISSUES EARLY WARNING REPORT IN CONNECTION WITH THE ACQUISITION OF SECURITIES OF AVICANNA INC.

Toronto, Ontario, March 21st, 2025 – Sheldon Inwentash (“Inwentash”) announces that through a series of transactions in recent weeks (the “Acquisitions”), ThreeD Capital Inc. (the “Joint Actor”) acquired ownership and control of an aggregate of 106,000 common shares (the “Subject Shares”) of Avicanna Inc. (the “Company” or “AVCN”). The Subject Shares represented approximately 0.1% of all issued and outstanding common shares of the Company. As a result of the Acquisitions, the percentage ownership held by Inwentash and the Joint Actor increased above 2%, on a partially diluted basis, from the last early warning report filed.

Immediately prior to the Acquisitions, Inwentash and the Joint Actor owned and controlled an aggregate of 19,056,800 common shares, 2,266,250 common share purchase warrants. And 50,000 stock options of the Company, representing approximately 17.3% of all issued and outstanding common shares of AVCN (or approximately 18.9% on a partially diluted basis, assuming exercise of the warrants and options held). Of this total, Inwentash held an aggregate of 6,068,957 common shares, 567,500 common share purchase warrants, and 50,000 options of the Company, representing approximately 5.5% of the issued and outstanding shares of AVCN (or approximately 6.0% on a partially diluted basis, assuming exercise of the warrants and options held). The Joint Actor held an aggregate of 12,987,800 common shares and 1,698,750 common share purchase warrants of the Company, representing approximately 11.8% of the issued and outstanding common shares of AVCN (or approximately 13.1% on a partially diluted basis, assuming exercise of the warrants held).

Immediately following the Acquisitions, Inwentash and the Joint Actor own and control an aggregate of 19,162,757 common shares, 2,266,250 common share purchase warrants. And 50,000 stock options of the Company, representing approximately 17.4% of all issued and outstanding common shares of AVCN (or approximately 19.1% on a partially diluted basis, assuming exercise of the warrants and options held). Of this total, Inwentash held an aggregate of 6,068,957 common shares, 567,500 common share purchase warrants, and 50,000 stock options of the Company, representing 5.5% of the issued and outstanding common shares of AVCN (or approximately 6.0% on a partially diluted basis, assuming exercise of the warrants and options held). The Joint Actor held an aggregate of 13,093,800 common shares and 1,698,750 common share purchase warrants of the Company, representing approximately 11.9% of the issued and outstanding common shares of AVCN (or approximately 13.2% on a partially diluted basis assuming the exercise of the warrants held).

The holdings of securities of the Company by Inwentash and the Joint Actor are managed for investment purposes. Inwentash and the Joint Actor could increase or decrease its investments in the Company at any time, or continue to maintain its current position, depending on market conditions or any other relevant factor.

The Subject Shares were acquired through the facilities of the Toronto Stock Exchange for total consideration of \$37,400, or approximately \$0.353 per Subject Share.

Additional Information

A copy of the applicable securities report filed in connection with the matters set forth above may be obtained by contacting:

Sheldon Inwentash
130 Spadina Avenue, Suite 401
Toronto, ON
M5V 2L4
Tel: 416-941-8900